SWITCH FROM A CNI- TO A BELATACEPT-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT RECIPIENTS IS SAFE AND RESULTS IN BETTER RENAL FUNCTION: 12 MONTH RESULTS FROM A PHASE II STUDY

2010 ◽  
Vol 90 ◽  
pp. 157 ◽  
Author(s):  
L. Rostaing ◽  
G. Nainan ◽  
M. C. Rial ◽  
S. Steinberg ◽  
F. Vincenti ◽  
...  
Keyword(s):  
Renal Function ◽  
Kidney Transplant ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Immunosuppressive Regimen ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly

2017 ◽  
Vol 17 (12) ◽  
pp. 3219-3227 ◽  
Author(s):  
F. Vincenti ◽  
G. Blancho ◽  
A. Durrbach ◽  
G. Grannas ◽  
J. Grinyó ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Randomized Phase Ii

Conversion to Everolimus in Kidney Transplant Recipients With Decreased Renal Function

2009 ◽  
Vol 41 (6) ◽  
pp. 2134-2136 ◽  
Author(s):  
A. Inza ◽  
S. Balda ◽  
E. Álvarez ◽  
S. Zárraga ◽  
F.J. Gaínza ◽  
...  
Keyword(s):  
Renal Function ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document